top of page

Search Results

Results found for "AntlerA Therapeutics"

  • 📰 GPCR Weekly News, August 7 to 13, 2023

    GPCR Symposium on 'GPCRs as Therapeutic Modalities'. Want to share your project in a casual way? npr-38 regulates avoidance and stress-induced sleep in Caenorhabditis elegans Towards the convergent therapeutic Provides Corporate Updates, and Reports Emerging Data from Chronic Neutropenia Clinical Program Structure Therapeutics

  • Discover the Hottest GPCR News of the Week: Oct 7-13, 2024!

    appreciate the incredible versatility of GPCRs and how small molecules can affect their behavior for therapeutic Learn how to therapeutically exploit GPCRs (Physiology’s ‘Swiss Army Knife’) vast repertoire of ways Adjust ligand kinetics and tissue disposition for optimal therapeutic activity.

  • GPR108 is required for gambogic acid inhibiting NF-κB signaling in cancer

    Herein, we identified GPR108, a GPCR protein described in innate immune system, is a potential therapeutic Overall, our findings supported GPR108 as a promising therapeutic target of cancer, and provided a small

  • 📰 GPCR Weekly News, January 29 to February 4, 2024

    Xavier Leroy for his new role as CEO of GIO Therapeutics Dr. Molecular mechanism of GPCR spatial organization at the plasma membrane Industry News Launch of GIO Therapeutics , founded by Cumulus Oncology, to develop therapeutics targeting G protein-coupled receptors to treat cancer and inflammation AVROBIO and Tectonic Therapeutic Announce Merger Trevena Inc Elevates Barry

  • Allosteric modulation of GPCRs: From structural insights to in silico drug discovery

    orthosteric site), allosteric modulators offer new avenues for the regulation of GPCR function with potential therapeutic today, will facilitate structure-based discovery and development of allosteric modulators as novel therapeutic

  • 📰 GPCR Weekly News, April 10 to 16, 2023

    Allosteric GPCR Drug Discovery from the 2nd Annual GPCRs-Targeted Drug Discovery Summit, Boston MA Pathios Therapeutics Michel Bouvier received the title of Doctor Honoris Causa from the Université de Montpellier Domain Therapeutics presented 3 posters at AACR 2023 Exscientia presented a poster at AACR 2023 Pathios Therapeutics presented Swiss Biotech Day (April 24 - 25, 2023) ASPET 2023 - American Society for Pharmacology and Experimental Therapeutics

  • 📰 GPCR Weekly News, March 25 to March 31, 2024

    cAMP-PKA-CREB signaling pathway based on network pharmacology and bioinformatics analysis Unveiling the therapeutic News Monash University pharmaceutical scientists honoured in NHMRC Research Excellence Awards Domain Therapeutics Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults Confo Therapeutics Development In Endocrine And Metabolic Diseases How biotech companies are using AI to design drugs GPCR Therapeutics

  • Inverse Agonists, Lymphatic Fixes & β-arrestin Tricks

    Collaboration is the catalyst—let’s redefine what’s possible in GPCR-driven therapeutics.   

  • RAB-Symposium - Regulatory Autoantibodies Targeting GPCRs. September 15-16, 2022. Lübeck, Germany...

    So far, numerous therapeutics targeting GPCRs have been developed, with a focus on small molecules and been associated with various disease-specific manifestations, highlighting a potential new area for therapeutic

  • Nanobodies: New Dimensions in GPCR Signaling Research

    the development of more selective drugs capable of modulating specific signaling pathways, improving therapeutic This allows for tailoring the half-life of nanobodies to increase their therapeutic window depending its conformation, protects the Schiff base, and prevents protein degradation, potentially offering therapeutic Nanobodies: A Review of Generation, Diagnostics and Therapeutics.

  • Pepducin-mediated G Protein-Coupled Receptor Signaling in the Cardiovascular System

    tools used to manipulate GPCR activity in an orthosteric site-independent manner to compounds with therapeutic development for each receptor, as well as the structural, signaling, pathophysiologic consequences, and therapeutic

  • 📰 GPCR Weekly News, March 13 to 19, 2023

    GPCRs in Oncology and Immunology Expanding role of CXCR2 and therapeutic potential of CXCR2 antagonists Reviews, GPCRs, and more The leukotriene B4 receptors BLT1 and BLT2 as potential therapeutic targets. It Will Participate For H1 2023 Learn more about Exscientia new pipeline candidate, EXS74539 Domain Therapeutics women-men professional equality index Octant introduces Hypatia, their New Robotic Drug Hunter GPCR Therapeutics

  • 📰 GPCR Weekly News, May 29 to June 4, 2023

    GPCR Activation and Signaling Therapeutic antagonism of the neurokinin 1 receptor in endosomes provides Industry News Structure Therapeutics Announces Poster Presentations of its Oral GLP-1 Receptor Agonist GSBR-1290 at the American Diabetes Association 83rd Scientific Sessions Domain Therapeutics' Nomination of DT-9045: A Groundbreaking NAM for Immunooncology Structure Therapeutics to Present at Jefferies Healthcare

  • 📰 GPCR Weekly News, June 19 to 25, 2023

    GPCR Partner, GPCR Therapeutics, for passing the Technology Evaluation process for listing on the KOSDAQ GPCR Therapeutics passes the Technology Evaluation process for listing on KOSDAQ. function" (June 28 - 30, 2023) FREE Seminar Antibodies targeting Membrane Proteins - From Antigen to New Therapeutics

  • Ben Clements on Rescuing Opioids with GPCR Modulators

    His work highlights how foundational GPCR science can drive therapeutic innovation.

  • Targeting Intracellular Allosteric Sites in GPCRs

    other GPCR-regulated systems such as free fatty acid receptors (FFARs), now regarded as targets for therapeutic and β-arrestin coupling, enabling the development of biased agonists and antagonists with distinct therapeutic Allosteric modulation is gaining prominence in GPCR therapeutics, with the discovery of an intracellular Biased allosteric modulators can enhance the safety and efficacy of GPCR-targeted therapeutics by selectively

  • 📢 Early Bird Registration Ends Tomorrow! | Sep 16 - 22, 2024

    Discovery on Target’s 19th Annual GPCR-Based Drug Discovery Targeting G Protein-Coupled Receptors for New Therapeutic INV-347 improves metabolic dysfunction in obese mice Aneesh Karatt Vellatt (CSO & Co-Founder, Maxion Therapeutics ) – BioLeader Interview Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK

  • 📰 GPCR Weekly News, May 27 to June 2, 2024

    tunes mGlu5 receptor function, impacting synaptic transmission Orphan receptor GPR88 as a potential therapeutic the neuropeptide Y4 receptor and its ligand pancreatic polypeptide from a structural, functional, and therapeutic Structural basis for selectivity and antagonism in extracellular GPCR-nanobodies Industry News Structure Therapeutics

  • 📰 GPCR Weekly News, August 21 to 27, 2023

    GPCR Symposium on 'GPCRs as Therapeutic Modalities'. neutrophil chemoattractant Neuroimmune interplay during type 2 inflammation: symptoms, mechanisms and therapeutic Launches with $33 Million Seed Round to Fuel its Drug Discovery Engine and Pipeline of Small Molecule Therapeutics

  • 📰 GPCR Weekly News, January 1 to 7, 2024

    Congratulations to Domain Therapeutics for appointing Michael Gottlieb as Chairman and Dr. of GPCRs in various states Reviews, GPCRs, and more G Protein-coupled Receptors (GPCRs) as Potential Therapeutics modulate engagement of CCR5 by chemokines by removing key electrostatic interactions Industry News Domain Therapeutics

  • 📰 GPCR Weekly News, April 15 to 21, 2024

    GPCRs in Oncology and Immunology Deciphering a GPCR-lncRNA-miRNA Nexus: Identification of an Aberrant Therapeutic Deorphanization of G Protein Coupled Receptors (GPCRs): a historical perspective Industry News Addex Therapeutics at the 19th Biopharma Drug Discovery Nexus Salipro Biotech will participate in BioKorea2024 Domain Therapeutics

  • 📰 GPCR Weekly News, September 25 to October 1, 2023

    of traditional Chinese medicine in the treatment of glioblastoma multiforme Industry News Structure Therapeutics Half-Year Financial Results and Exciting Developments at Aelis Farma Ion Channel Drug Developer Maxion Therapeutics Lefkowitz's Career at Duke October 3, 2023, | FREE Seminar: Changing paradigm on Therapeutics targeting

  • 📰 GPCR Weekly News, September 18 to 24, 2023

    GPCR Symposium about 'GPCRs as Therapeutic Modalities' rocked it! recommended by NICE for acute migraines Addex mGlu2 NAM Cognition Program Receives €4 Million Grant Confo Therapeutics Lefkowitz's Career at Duke October 3, 2023, | FREE Seminar: Changing paradigm on Therapeutics targeting

  • Orion and Peptilogics are pursuing AI-driven drug discovery to explore new functional chemical ...

    are pursuing AI-driven drug discovery to explore new functional chemical space and precision-engineer therapeutics

  • Sosei Heptares and Kallyope Enter Collaboration to Identify and Validate Novel Gastrointestinal GPCR

    leverage multiple sophisticated technologies that drive creation of new drug discovery programs in key therapeutic biology platform to identify potential GPCR targets and advance the development of new gastrointestinal therapeutics

  • 📰 Breaking Down the Latest GPCR Discoveries: a Weekly Update (Nov 27-Dec 3, 2023)

    activity, and structural evaluation Flavonoids as G Protein-coupled Receptors Ligands: New Potential Therapeutic back GPCR agonist after GSK changes course All-rounder among receptors inspires drug research Tectonic Therapeutic Announces Acceptance of Abstract Examining the Use of OLINVYK in Patients with Acute Burn Injuries Carmot Therapeutics

  • Unlock the Future of GPCR Science: Breakthroughs and Courses Await | Sep 2 - Sep 8, 2024

    Discovery on Target’s 19th Annual GPCR-Based Drug Discovery Targeting G Protein-Coupled Receptors for New Therapeutic September 2nd to 8th, 2024 Industry News Superluminal Medicines Closes $120 Million Series A Round Domain Therapeutics Heterodimer, TAS1R2/1R3 GPCRs in Neuroscience GPCR-Mediated Natural Products and Compounds: Potential Therapeutic

  • Discovery On Target, October 17-20, 2022, Boston, USA

    and technologies, as well as target validation strategies for the discovery and development of novel therapeutic

  • Building Backwards: Why Top-Down Models Could Revolutionize Pain Research

    how inflammation, cognition, and pain circuits overlap , and how GPCRs might serve as more responsive therapeutic

  • 📰 GPCR Weekly News, April 3 to 9, 2023

    GPCRs in Neuroscience G protein-coupled receptors (GPCRs) as Potential Therapeutics for Psychiatric Disorders Domain Therapeutics to present three posters at AACR 2023 annual meeting. Biotech Day (April 24 - 25, 2023) NEW ASPET 2023 - American Society for Pharmacology and Experimental Therapeutics

bottom of page